Capecitabine/Bevacizumab Compared to Capecitabine Alone in Pretreated Metastatic Breast Cancer: Results of a Phase III Study)
- 1 February 2003
- journal article
- Published by Elsevier in Clinical Breast Cancer
- Vol. 3 (6) , 375-377
- https://doi.org/10.1016/s1526-8209(11)70270-1
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclinesBritish Journal of Cancer, 2002
- Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patientsCancer, 2001
- Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancerAnnals of Oncology, 2001
- Capecitabine: The new standard in metastatic breast cancer failing anthracycline and taxane-containing chemotherapy? Mature results of a large multicenter phase II trialEuropean Journal Of Cancer, 2001
- Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast CancerJournal of Clinical Oncology, 1999
- The implications of angiogenesis for the biology and therapy of cancer metastasisCell, 1994